Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2005 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00066274
First received: August 6, 2003
Last updated: January 10, 2009
Last verified: May 2005

August 6, 2003
January 10, 2009
May 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00066274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying combination chemotherapy containing irinotecan and oxaliplatin to see how well it works compared to two standard combination chemotherapy regimens in treating patients with unresectable metastatic colorectal cancer.

OBJECTIVES:

  • Compare the efficacy, in terms of response rate (partial response and complete response), of irinotecan and oxaliplatin vs irinotecan, fluorouracil, and leucovorin calcium vs oxaliplatin, fluorouracil, and leucovorin calcium in patients with metastatic colorectal cancer.
  • Compare the progression-free survival of patients treated with these regimens.
  • Compare the tolerability of these regimens in these patients.
  • Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1.
  • Arm II: Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1-2.
  • Arm III: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours on days 1-2.

In all arms, treatment repeats every 2 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and then every 3 months for 1 year.

Patients are followed at 2 months.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study within 1 year.

Interventional
Phase 2
Allocation: Randomized
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: FOLFIRI regimen
  • Drug: FOLFOX regimen
  • Drug: fluorouracil
  • Drug: irinotecan hydrochloride
  • Drug: leucovorin calcium
  • Drug: oxaliplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed colorectal carcinoma

    • Metastatic disease
  • Not amenable to surgery
  • Unidimensionally measurable disease
  • No bone metastases
  • No brain metastases

PATIENT CHARACTERISTICS:

Age

  • 18 to 75

Performance status

  • WHO 0-2

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Neutrophil count at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL

Hepatic

  • Bilirubin no greater than 1.25 times upper limit of normal (ULN) (1.5 times ULN if hepatic metastases are present)
  • SGPT and SGOT no greater than 3 times ULN (5 times ULN if hepatic metastases are present)

Renal

  • Creatinine no greater than 1.25 times ULN

Cardiac

  • No concurrent cardiac abnormalities that would preclude study therapy

Pulmonary

  • No concurrent pulmonary abnormalities that would preclude study therapy

Other

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No chronic enteropathy
  • No other prior cancer within the past 5 years except carcinoma in situ of the cervix or curatively treated basal cell skin cancer
  • No concurrent severe uncontrolled infection
  • No obstruction or partial obstruction that would interfere with study therapy
  • No psychological, social, familial, or geographical situation that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent anticancer biological response modifiers

Chemotherapy

  • No prior chemotherapy (except adjuvant chemotherapy completed more than 6 months ago)
  • No prior irinotecan
  • No prior oxaliplatin
  • No other concurrent chemotherapy

Endocrine therapy

  • No concurrent anticancer hormonal therapy

Radiotherapy

  • At least 4 weeks since prior pelvic radiotherapy
  • No prior abdominopelvic radiotherapy

Surgery

  • At least 4 weeks since prior surgery
  • No prior extensive intestinal resection (i.e., more than 1 prior hemicolectomy or extensive resection of the small intestines)

Other

  • No other concurrent experimental medication
  • No other concurrent anticancer therapy
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00066274
CDR0000315384, FRE-FNCLCC-ACCORD-08/0103, EU-20233
Not Provided
Not Provided
UNICANCER
Not Provided
Study Chair: Yves Becouarn, MD Institut Bergonié
National Cancer Institute (NCI)
May 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP